A Whole-Person Approach to Navigating Colorectal Cancer Care

A colorectal cancer diagnosis reorganizes a person’s life within a matter of days. Appointments accumulate, decisions arrive quickly, and patients are often asked to weigh surgery, chemotherapy, radiation, and immunotherapy before they have had time to absorb what has happened. In the middle of that process, many patients begin asking a second set of questions: how do I tolerate this treatment well, how do I protect my strength, and what can I do that supports the plan my oncology team has already recommended. Those questions are legitimate, and they deserve clinical answers rather than internet speculation.

At The Center for Advanced Medicine, Dr. Jonathan Stegall and the clinical team work with patients who want conventional colorectal cancer treatment supported by evidence-informed integrative care. The practice does not position integrative therapy as a substitute for oncology. It exists to complement it, under physician supervision, with attention to nutrition, symptom burden, functional capacity, and emotional wellbeing alongside the tumor itself. This article explains what whole-person colorectal cancer care means, what it can and cannot do, and how patients and families can evaluate it realistically.

Understanding Whole-Person Colorectal Cancer Care

Colorectal cancer refers to malignancies arising in the colon or the rectum, most often from precancerous polyps that develop over years. Standard treatment is guided by stage, tumor location, molecular features such as microsatellite instability and RAS or BRAF status, and the patient’s overall health. Depending on those factors, care may include surgical resection, adjuvant or neoadjuvant chemotherapy, radiation for rectal disease, targeted agents, or immunotherapy. These modalities remain the foundation of curative and life-extending treatment, and nothing described here replaces them.

Whole-person care refers to the structured clinical attention given to everything surrounding that treatment. It includes nutritional status, physical conditioning, gastrointestinal function, neuropathy, sleep, anxiety, and the practical realities of living through months of therapy. Integrative oncology is the discipline that studies and delivers these supportive interventions in a rigorous way. As Mao and colleagues described in CA: A Cancer Journal for Clinicians in 2022, integrative oncology is defined as a patient-centered, evidence-informed field that uses mind and body practices, natural products, and lifestyle modifications alongside conventional cancer treatment.

The distinction matters. Integrative oncology is not alternative medicine and is not an argument against chemotherapy or surgery. It is a set of adjunctive strategies applied by physicians who understand the underlying oncologic plan. Patients considering this approach can review the practice explanation of what integrative oncology is as a starting point for that conversation.

Where Integrative Care Fits in the Treatment Timeline

Integrative support can be introduced at nearly any point: before surgery to optimize nutritional and functional reserve, during chemotherapy to address tolerability, and after active treatment during survivorship. Each phase has different priorities. Prehabilitation emphasizes protein intake, strength, and readiness for an operation. Active treatment emphasizes symptom control and maintaining dose intensity. Survivorship emphasizes recurrence risk reduction, bowel function, and return to normal life.

Common Patient Concerns With Colorectal Cancer

Patients with colorectal cancer carry a distinct set of concerns, and they are worth naming plainly. Bowel function is often the first. After resection, and particularly after low anterior resection for rectal cancer, patients may experience urgency, frequency, clustering of stools, or incontinence. These changes affect work, travel, intimacy, and social confidence, and many patients hesitate to raise them. A whole-person program treats bowel function as a central clinical concern rather than a minor side effect.

Ostomy adjustment is a second concern. Whether temporary or permanent, an ostomy requires learning, dietary adaptation, and emotional processing. Patients frequently describe feeling changed in how they see their bodies, and cultural or religious considerations around cleanliness, food, and privacy can add complexity. Care that respects those considerations, rather than treating them as obstacles, tends to produce better adherence and less isolation.

Chemotherapy tolerability is a third. Oxaliplatin-based regimens commonly used in colon cancer carry a risk of cumulative peripheral neuropathy, and fluoropyrimidines can cause mucositis, diarrhea, fatigue, and hand-foot syndrome. Patients understandably worry about dose reductions or early discontinuation. Supportive care that reduces symptom burden may help patients complete the treatment their oncologist intended, which is one of the most practical goals integrative care can serve.

Fear of Recurrence and the Emotional Load

Anxiety about recurrence does not end when treatment ends. Surveillance imaging, carcinoembryonic antigen testing, and colonoscopy intervals create recurring periods of heightened stress. Younger patients, whose incidence of colorectal cancer has been rising, often face this alongside careers and young families. At The Center for Advanced Medicine, emotional and psychological support is treated as part of the clinical plan rather than an optional extra, delivered through mind-body medicine and ongoing physician contact.

Therapies Used and How Dr. Stegall Customizes Care

The Center for Advanced Medicine is structured around a single focus: cancer care. Dr. Jonathan Stegall completed internal medicine residency training through Yale University School of Medicine and a fellowship in integrative oncology through the Metabolic Medical Institute, and he built the practice to blend conventional treatment with adjunctive therapies in one coordinated program. Patients can review his background on the about Dr. Stegall page.

Care planning begins with data. Comprehensive baseline lab testing establishes nutritional status, inflammatory markers, metabolic parameters, and organ function, which informs what is appropriate and what is not. For patients whose oncologic situation warrants it, molecular residual disease testing such as Signatera may be discussed with the treating team. Testing is used to individualize supportive care and to monitor safety, not to replace standard staging or surveillance directed by the patient’s oncologist.

Nutrition as a Clinical Intervention

Diet is one of the better-studied areas in colorectal cancer survivorship. Van Blarigan and colleagues, publishing in JAMA Network Open in 2022, examined dietary intake in patients with stage III colon cancer enrolled in a randomized adjuvant therapy trial and analyzed associations between unprocessed red meat and processed meat intake and outcomes including recurrence and mortality. Findings of this kind are why the practice treats nutrition and cancer as a clinical service with individualized counseling rather than generic handouts, with attention to protein adequacy, fiber tolerance after resection, and the specific restrictions an ostomy may require.

Adjunctive Therapies Offered

The practice offers a defined set of adjunctive treatments that may be considered depending on the individual case, including intravenous vitamin C, mistletoe therapy, lymphatic therapy, pulsed electromagnetic field therapy, and repurposed medications. Conventional chemotherapy may also be delivered within the integrative framework when clinically appropriate. Each of these is discussed in terms of what the evidence does and does not currently support, potential interactions with active oncologic therapy, and the patient’s own goals. Any therapy that could interfere with chemotherapy, radiation, or immunotherapy is reviewed carefully, and coordination with the treating oncologist is expected rather than l.

Physical Activity and Function

Exercise has become one of the most compelling supportive interventions in colon cancer specifically. Courneya and colleagues reported the results of the CHALLENGE trial in the New England Journal of Medicine in 2025, evaluating a structured exercise program in patients who had completed adjuvant chemotherapy for colon cancer. Broader guidance from Ligibel and colleagues, summarized in JCO Oncology Practice in 2022, addresses exercise, diet, and weight management during cancer treatment. Activity prescriptions in the program are individualized to surgical recovery, neuropathy, and baseline conditioning rather than applied uniformly.

Recovery, Outcomes, and Realistic Expectations

Recovery from colorectal cancer treatment is measured in months, not weeks, and it is rarely linear. After open or laparoscopic resection, patients typically resume light activity within several weeks, while bowel function continues to change for six to twelve months, sometimes longer after rectal surgery. Chemotherapy-related fatigue often persists for a period after the final cycle. Understanding this timeline in advance reduces the sense that a slow week represents failure.

Integrative care should be described in honest terms. The reasonable goals are better symptom control, improved nutritional and functional status, reduced treatment interruptions, and better quality of life during and after therapy. Adjunctive therapies are not curative, and no responsible physician can promise that they will eliminate disease, prevent recurrence, or allow a patient to forgo standard treatment. Dr. Stegall and the team at The Center for Advanced Medicine frame expectations this way from the first visit.

How Progress Is Measured

Progress is tracked through objective and subjective measures together: laboratory trends, weight and body composition, performance status, symptom scores, chemotherapy dose intensity, and the patient’s own report of how they are living. Oncologic response continues to be assessed by the treating oncology team through imaging and tumor markers. The two streams of information are meant to inform one another, which is why open communication between the practice and the patient’s oncologist matters so much.

Who Is and Is Not an Appropriate Candidate

Appropriate candidates are generally patients with colorectal cancer who are receiving, preparing for, or have completed conventional treatment, and who want structured supportive care alongside it. This includes patients on adjuvant chemotherapy who are struggling with tolerability, post-surgical patients working to rebuild strength and bowel function, survivors focused on long-term risk reduction, and patients with advanced disease seeking symptom relief and quality of life support in parallel with oncologic management or palliative care.

Integrative care is not appropriate for a patient who intends to decline or delay recommended surgery, chemotherapy, radiation, or immunotherapy in favor of adjunctive therapies. That is not what this program is for, and patients who want that path are not good candidates. It is also less suitable for patients who are unwilling to allow communication with their oncology team, since safe coordination depends on it. Certain individual therapies may be contraindicated because of organ function, drug interactions, clinical trial protocol requirements, or specific medical history, and these determinations are made case by case.

Practical Considerations

Patients travel to the practice from across the country, and the becoming a patient process outlines how care is coordinated, including records review and scheduling. Candidacy, treatment intensity, visit frequency, and travel logistics are all discussed openly during the initial consultation so that families can make an informed decision rather than an anxious one.

Scheduling a Consultation

Colorectal cancer care is demanding, and no patient should have to assemble a supportive care plan alone from fragmented sources. The Center for Advanced Medicine offers a physician-led evaluation in which Dr. Jonathan Stegall reviews your diagnosis, staging, current oncologic plan, laboratory data, symptoms, and goals, then explains clearly what integrative support could reasonably add and what it cannot. If the answer is that your current plan is already well constructed, you will be told that directly.

If you or someone you love is navigating colorectal cancer and wants care that considers the whole person alongside standard oncology, you are invited to contact The Center for Advanced Medicine to discuss whether a consultation is appropriate. Please continue working with your treating oncologist, and bring this conversation to them as well. Coordinated, transparent care is the point.